Anti-SpeB Small Molecule Inhibitor Library Can Be Synthesized Using a Fluorosulfonyl 2,3-Dimethyl Imidazol-3-Ium Triflate Salt in a SuFEx Reaction

Faculty Mentor Information

Dr. Sarah Hobdey (Mentor), Idaho Veterans Research and Education Foundation; and Dr. Don Warner (Mentor), Boise State University

Abstract

Infection by the group A streptococcus (GAS) bacteria Streptococcus pyogenes can result in a disease state called necrotizing fasciitis. This disease can progress rapidly, resulting in amputation or death. During infection, GAS produces a cysteine protease called Streptococcal Pyrogenic Exotoxin B (SpeB), which contributes to immune evasion by hydrolysis of host IgG. Lead modification of a small molecule inhibitor (SMI) for SpeB can create a therapeutic solution for GAS infection to allow for proper host immune response against GAS. Two analogs have been identified to have significant anti-SpeB activity, however the synthesis of these analogs is difficult due to a gaseous reagent that is both hard to obtain and dangerous to use. Alternative synthesis schemes using a safer and more available reagent creates a bioisostere (sulfonyl) of the product from the original synthesis scheme (imino fluoro sulfoxide). From this adduct, sulfur-fluoride exchange (SuFEx) click chemistry can be done to create a library of SMIs. A fluorometric biochemical assay measuring the hydrolytic activity of SpeB is utilized to screen for optimized leads on the criteria of efficacy and potency.

This document is currently not available here.

Share

COinS
 

Anti-SpeB Small Molecule Inhibitor Library Can Be Synthesized Using a Fluorosulfonyl 2,3-Dimethyl Imidazol-3-Ium Triflate Salt in a SuFEx Reaction

Infection by the group A streptococcus (GAS) bacteria Streptococcus pyogenes can result in a disease state called necrotizing fasciitis. This disease can progress rapidly, resulting in amputation or death. During infection, GAS produces a cysteine protease called Streptococcal Pyrogenic Exotoxin B (SpeB), which contributes to immune evasion by hydrolysis of host IgG. Lead modification of a small molecule inhibitor (SMI) for SpeB can create a therapeutic solution for GAS infection to allow for proper host immune response against GAS. Two analogs have been identified to have significant anti-SpeB activity, however the synthesis of these analogs is difficult due to a gaseous reagent that is both hard to obtain and dangerous to use. Alternative synthesis schemes using a safer and more available reagent creates a bioisostere (sulfonyl) of the product from the original synthesis scheme (imino fluoro sulfoxide). From this adduct, sulfur-fluoride exchange (SuFEx) click chemistry can be done to create a library of SMIs. A fluorometric biochemical assay measuring the hydrolytic activity of SpeB is utilized to screen for optimized leads on the criteria of efficacy and potency.